{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:08:44Z","timestamp":1789427324558,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67589-5","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:33:31Z","timestamp":1766309611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0940-3001","authenticated-orcid":false,"given":"Zixiang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-0532","authenticated-orcid":false,"given":"Chuanqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-6763","authenticated-orcid":false,"given":"Fuxiang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-5387","authenticated-orcid":false,"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"67589_CR1","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","volume":"69","author":"M Arnold","year":"2021","unstructured":"Arnold, M., Ferlay, J., van Berge Henegouwen, M. I. & Soerjomataram, I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 69, 1564\u20131571 (2021).","journal-title":"Gut"},{"key":"67589_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","volume":"29","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat. Med. 29, 473\u2013482 (2023).","journal-title":"Nat. Med."},{"key":"67589_CR3","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","volume":"13","author":"DJ Uhlenhopp","year":"2020","unstructured":"Uhlenhopp, D. J., Then, E. O., Sunkara, T. & Gaduputi, V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin. J. Gastroenterol. 13, 1010\u20131021 (2020).","journal-title":"Clin. J. Gastroenterol."},{"key":"67589_CR4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400\u2013412 (2013).","journal-title":"Lancet"},{"key":"67589_CR5","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1, R. et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 992\u20131004 (2022).","journal-title":"Ann. Oncol."},{"key":"67589_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang, H. et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann. Oncol. 34, 163\u2013172 (2023).","journal-title":"Ann. Oncol."},{"key":"67589_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato, K. et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet 404, 55\u201366 (2024).","journal-title":"Lancet"},{"key":"67589_CR8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191\u20131203 (2021).","journal-title":"N. Engl. J. Med."},{"key":"67589_CR9","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","volume":"29","author":"J Yin","year":"2023","unstructured":"Yin, J. et al. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat. Med. 29, 2068\u20132078 (2023).","journal-title":"Nat. Med."},{"key":"67589_CR10","doi-asserted-by":"crossref","first-page":"1051841","DOI":"10.3389\/fimmu.2022.1051841","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q., Liu, T. & Ding, Z. Neoadjuvant immunotherapy for resectable esophageal cancer: a review. Front. Immunol. 13, 1051841 (2022).","journal-title":"Front. Immunol."},{"key":"67589_CR11","first-page":"e6234","volume":"11","author":"X Song","year":"2023","unstructured":"Song, X. et al. Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. J. Immunother. Cancer 11, e6234 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"67589_CR12","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin, J. et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat. Med. 30, 2549\u20132557 (2024).","journal-title":"Nat. Med."},{"key":"67589_CR13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J Sun","year":"2021","unstructured":"Sun, J. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759\u2013771 (2021).","journal-title":"Lancet"},{"key":"67589_CR14","first-page":"17","volume":"45","author":"Y Glasson","year":"2023","unstructured":"Glasson, Y. et al. Single-cell high-dimensional imaging mass cytometry: one step beyond in oncology. Semin. Immunopathol. 45, 17\u201328 (2023).","journal-title":"Semin. Immunopathol."},{"key":"67589_CR15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study. Signal Transduct. Target. Ther. 9, 280 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"67589_CR16","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/s41388-024-03123-z","volume":"43","author":"C Wu","year":"2024","unstructured":"Wu, C. et al. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. Oncogene 43, 2751\u20132767 (2024).","journal-title":"Oncogene"},{"key":"67589_CR17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","volume":"42","author":"X Shang","year":"2024","unstructured":"Shang, X. et al. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the Keystone-001 trial. Cancer Cell 42, 1747\u20131763 (2024).","journal-title":"Cancer Cell"},{"key":"67589_CR18","doi-asserted-by":"crossref","first-page":"102579","DOI":"10.1016\/j.eclinm.2024.102579","volume":"71","author":"Z Wu","year":"2024","unstructured":"Wu, Z. et al. Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial. Eclinicalmedicine 71, 102579 (2024).","journal-title":"Eclinicalmedicine"},{"key":"67589_CR19","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang, H. et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J. Clin. Oncol. 36, 2796\u20132803 (2018).","journal-title":"J. Clin. Oncol."},{"key":"67589_CR20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","volume":"32","author":"C Mariette","year":"2014","unstructured":"Mariette, C. et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III Trial FFCD 9901. J. Clin. Oncol. 32, 2416\u20132422 (2014).","journal-title":"J. Clin. Oncol."},{"key":"67589_CR21","doi-asserted-by":"crossref","first-page":"e7076","DOI":"10.1002\/cam4.7076","volume":"13","author":"CE Gaber","year":"2024","unstructured":"Gaber, C. E. et al. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a systematic review and meta-analysis. Cancer Med. 13, e7076 (2024).","journal-title":"Cancer Med."},{"key":"67589_CR22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","volume":"7","author":"A Pataer","year":"2012","unstructured":"Pataer, A. et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J. Thorac. Oncol. 7, 825\u2013832 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"67589_CR23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.21037\/atm-21-3331","volume":"9","author":"J Shen","year":"2021","unstructured":"Shen, J. et al. Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010). Ann. Transl. Med. 9, 1516 (2021).","journal-title":"Ann. Transl. Med."},{"key":"67589_CR24","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang, H., Wang, F., Hallemeier, C. L., Lerut, T. & Fu, J. Oesophageal cancer. Lancet 404, 1991\u20132005 (2024).","journal-title":"Lancet"},{"key":"67589_CR25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","volume":"151","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study. Int. J. Cancer 151, 128\u2013137 (2022).","journal-title":"Int. J. Cancer"},{"key":"67589_CR26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","volume":"144","author":"C Li","year":"2021","unstructured":"Li, C. et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur. J. Cancer 144, 232\u2013241 (2021).","journal-title":"Eur. J. Cancer"},{"key":"67589_CR27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0140-6736(12)60516-9","volume":"379","author":"SS Biere","year":"2012","unstructured":"Biere, S. S. et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379, 1887\u20131892 (2012).","journal-title":"Lancet"},{"key":"67589_CR28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SLA.0b013e3182590603","volume":"256","author":"JD Luketich","year":"2012","unstructured":"Luketich, J. D. et al. Outcomes after minimally invasive esophagectomy. Ann. Surg. 256, 95\u2013103 (2012).","journal-title":"Ann. Surg."},{"key":"67589_CR29","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(02)08651-8","volume":"359","author":"MRCO Group","year":"2002","unstructured":"Group, M. R. C. O. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359, 1727\u20131733 (2002).","journal-title":"Lancet"},{"key":"67589_CR30","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074\u20132084 (2012).","journal-title":"N. Engl. J. Med."},{"key":"67589_CR31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41392-024-01988-w","volume":"9","author":"S Huang","year":"2024","unstructured":"Huang, S. et al. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. Signal Transduct. Target. Ther. 9, 285 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"67589_CR32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41419-025-07787-7","volume":"16","author":"J Luo","year":"2025","unstructured":"Luo, J. et al. ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma. Cell Death Dis. 16, 462 (2025).","journal-title":"Cell Death Dis."},{"key":"67589_CR33","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/0008-5472.CAN-15-2630","volume":"76","author":"A Filatova","year":"2016","unstructured":"Filatova, A. et al. Acidosis Acts through HSP90 in a PHD\/VHL-Independent Manner to Promote HIF Function and Stem Cell Maintenance in Glioma. Cancer Res 76, 5845\u20135856 (2016).","journal-title":"Cancer Res"},{"key":"67589_CR34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12943-025-02228-7","volume":"24","author":"Y Pan","year":"2025","unstructured":"Pan, Y. et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol. Cancer 24, 22\u201352 (2025).","journal-title":"Mol. Cancer"},{"key":"67589_CR35","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/15384047.2020.1763147","volume":"21","author":"S Min","year":"2020","unstructured":"Min, S. et al. Chetomin, a Hsp90\/HIF1\u03b1 pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells. Cancer Biol. Ther. 21, 698\u2013708 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"67589_CR36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J. Hepatol. 78, 770\u2013782 (2023).","journal-title":"J. Hepatol."},{"key":"67589_CR37","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/s41467-024-49282-1","volume":"15","author":"A Varveri","year":"2024","unstructured":"Varveri, A. et al. Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development. Nat. Commun. 15, 4988 (2024).","journal-title":"Nat. Commun."},{"key":"67589_CR38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","volume":"5","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat. Cancer 5, 167\u2013186 (2024).","journal-title":"Nat. Cancer"},{"key":"67589_CR39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67589_CR40","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"67589_CR41","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1200\/JCO.22.01490","volume":"41","author":"H Wu","year":"2023","unstructured":"Wu, H. et al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1\u2013expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J. Clin. Oncol. 41, 1735\u20131746 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67589-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67589-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:12:35Z","timestamp":1769213555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67589-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67589"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67589-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"871"}}